Articles related to RADIOTHERAPY

UT Southwestern’s pioneering use of SCINTIX biology-guided radiotherapy represents a major advancement in precision oncology, targeting bone and lung cancers with a novel approach that combines PET imaging and radiotherapy for more effective treatment.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

The GCIG INTERLACE study has demonstrated a significant improvement in 5-year survival rates in advanced cervical cancer, from 72% to 80%, with the addition of induction chemotherapy to standard-of-care chemoradiation.

The study’s findings suggest that palliative radiotherapy could be a viable option for managing pain in multiple myeloma patients. With a complete response rate of 48% and a partial response rate of 38%, this treatment approach shows promise.

With a complete metabolic response rate of 82.1% after just four cycles of induction, this new regimen could change how we approach treatment for young patients with low risk, relapsed classical Hodgkin lymphoma.